Kymera Therapeutics presents new clinical data from the ongoing Phase 1 trial of potent, highly selective STAT3 Degrader KT-333, a historically undrugged transcription factor at EHA Annual Meeting KT-333 demonstrated initial clinical proof of concept across multiple hematological malignancies, including complete responses in two patients with Hodgkin’s lymphoma Robust STAT3 knockdown and positive immunomodulatory effect achieved in blood and tumor Well-tolerated with Phase 1 dose escalation ongoing and additional data expected in the second half of 2024 https://lnkd.in/gxFube6Z
Gagan Kukreja’s Post
More Relevant Posts
-
Yesterday, we presented positive initial results from our first-in-human Phase 1 #ClinicalTrial of SYNCAR-001 + STK-009, our orthogonal IL-2 and CD19 #CART investigational therapy, for the treatment of relapsed or refractory CD19+ hematologic malignancies at the 66th American Society of Hematology Annual Meeting and Exposition. Data presented on the combination of STK-009 and a low dose of SYNCAR-001 cells demonstrate a favorable safety profile without dose-limiting or IL-2 related toxicities, as well as durable responses, including complete responses in 4 of 4 patients with non-Hodgkin lymphoma. We are encouraged by the ongoing validation of our orthogonal IL-2 technology and look forward to evaluating SYNCAR-001 + STK-009 in patients without lymphodepleting chemotherapy. Learn more about the results here: https://lnkd.in/gdwcxZbC View the poster here: https://lnkd.in/g7BEhW68
To view or add a comment, sign in
-
Today we announced our first abstract on CRG-023 to be presented at the @American Society of Hematology Annual Meeting in San Diego. CRG-023 is a CD19-, CD20- and CD22-targeting tri-specific, tri-cistronic CAR T product candidate designed to provide more patients with a broad range of B-cell malignancies with durable responses, resulting in a potential best-in-class CAR T-cell therapy. Encouraging preclinical data showed sustained, durable anti-B cell lymphoma activity. CRG-023 represents the next step in our mission to develop best-in-class, potentially curative CAR T-cell therapies. Read more about the abstract and poster presentation details here: https://bit.ly/3UD0vlS #ASH24 #celltherapy
To view or add a comment, sign in
-
Excitement is building as #ASH24 approaches! Be sure to catch Dr. Matthew J. Cortese, MD, MPH, presenting his research on groundbreaking topics: 📅 December 7: Oral presentation on "Multiomic Evaluation of Immunologic Changes in Chronic Lymphocytic Leukemia with Venetoclax Treatment." 📅 December 8: Oral presentation on "Clinical Outcomes of Transformed Follicular Lymphoma with CAR T-Cell Therapy: A US Multicenter Real-World Analysis." Poster presentation on "A Phase 1 Study to Evaluate the Safety and Tolerability of a Combination Autologous CD19 CAR T Cell Therapy (SYNCAR-001) and Orthogonal IL-2 (STK-009) in Subjects with Relapsed or Refractory CD19 Expressing Hematologic Malignancies (NCT05665062)." 💬 Connect with Dr. Cortese at booth 3417 or schedule a meeting to dive deeper into Roswell Park's impactful contributions to hematology research. 🔗 Schedule here: https://lnkd.in/gEZXsbVe We can’t wait to see you there!
To view or add a comment, sign in
-
Innate Pharma and the IFLI - Institute for Follicular Lymphoma Innovation are pleased to announce a new agreement to clinically study the potential of IPH6501, Innate's anti-CD20 ANKET® in Follicular Lymphoma. Patients with R/R Follicular Lymphoma will be included in the ongoing Phase 1/2 trial investigating IPH6501 in patients with R/R CD20+ Non-Hodgkin Lymphoma To support Innate and the investigation of IPH6501 in Follicular Lymphoma, the IFLI will invest up to $7.9M. Learn more: https://lnkd.in/gmygWPZU #InnatePharma #ANKET #agreement #FollicularLymphoma
To view or add a comment, sign in
-
Multispecific antibody shows promise in B cell lymphoma A multispecific antibody candidate for B cell lymphoma preferentially engaged CD47 in presence of co-engagement of CD20 and CD19, in preclinical investigations. One dose of Nutcracker Therapeutics’ NTX-472 in vivo rapidly depleted B cells with no detectable binding to red blood cells. The results were presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. https://lnkd.in/eUrV4yuS #Antibodies #ASCO #Lymphoma
To view or add a comment, sign in
-
✨ Join Our Webinar: B Cell Lymphoma Patient-Derived Lymph Node Organoids in GrowDex®-T! We’re starting today at 4:00 PM - 4:45 PM EEST! We’re excited to invite you to our Meet the expert -webinar hosted by UPM Biomedicals, featuring Jelena Gnjatovic, a doctoral researcher in Clinical Oncology from the University of Turku's Doctoral Programme in Clinical Research. What Will You Learn? 🌟 Explore a Groundbreaking B Cell Lymphoma 3D Model: Discover how GrowDex-T nanocellulose hydrogel is used to replicate the cancerous tissue environment without the need for complex co-cultures. 🌟 Cost-Effective and Reproducible Method: Learn how this model creates lymph node organoids efficiently, simplifying the experimental process while minimizing complications. 🌟 Improve Ex Vivo Drug Testing Reliability: Understand how this model enhances the accuracy and consistency of drug testing in B cell lymphoma research, paving the way for more effective therapies. 👉 Register now to join us and gain valuable insights from our expert: https://lnkd.in/exgHPhje
To view or add a comment, sign in
-
Excited to share my latest article: FDA Approval Summary: Polatuzumab Vedotin in the First-Line Treatment of Select Large B-cell Lymphomas! In this piece, I explore the recent FDA approval of Polatuzumab Vedotin (Polivy) and its impact on the treatment landscape for large B-cell lymphomas. This therapy is a significant step forward, offering another option for patients with lymphoma. I dive into the clinical data, regulatory insights and Oncology Drug Advisory Committee (ODAC) meeting and what this approval means for both patients and healthcare professionals. You can read the full article here: https://lnkd.in/ggcBzrzD #FDA #Polatuzumab vedotin #Lymphoma #Oncology #CancerCare #HealthcareInnovation #MedicalResearch #odac #FDAoncology #FDAwomen
To view or add a comment, sign in
-
Highlighting Immunotherapy as first line treatment of advance Hodgkin disease A recent trial by Dr. Herrera from City of Hope compared first line treatment of advanced stage Hodgkin lymphoma patients with #Nivolumab or #Brentuximab combined with traditional AVD chemotherapy. The initial result after nearly two year follow-up of approximately 1000 patients showed better progression free survival in patients treated with #Nivolumab. N+AVD resulted in longer progression-free survival than BV+AVD in adolescents and adults with stage III or IV advanced-stage classic Hodgkin’s lymphoma and had a better side-effect profile. #Hodgkin #Nivolumab #Immunotherapy #Lymphoma https://lnkd.in/d58GVr8t
Nivolumab in Advanced Hodgkin’s Lymphoma | NEJM
nejm.org
To view or add a comment, sign in
-
A significant step forward in the battle against large B-cell lymphoma (LBCL)! NeoImmuneTech's groundbreaking research presented at ESMO 2024 highlights the potential of combining CAR-T cell therapy with their innovative drug, NT-I7. Early data suggests this combination is not only safe but also leads to a substantial increase in CAR-T cell expansion and persistence. This promising development could mean improved clinical outcomes for those battling this aggressive form of non-Hodgkin lymphoma. #LBCL #CGT #NeoImmuneTech
To view or add a comment, sign in
-
In FORT-2, rogaratinib and atezolizumab showed tolerable safety with a high objective response rate (54%) in patients with FGFR mRNA-overexpressing urothelial cancer. Patient selection by mRNA FGFR3 overexpression may expand FGFR inhibitor benefit. https://ja.ma/3MSi9xu
To view or add a comment, sign in